sialorrhea pipeline insight

DelveInsight’s, “Sialorrhea – Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Sialorrhea Understanding

Sialorrhea: Overview

Sialorrhea, drooling or excessive salivation is a common problem in neurologically impaired children and in adults who have Parkinson's disease or have had a stroke. It is most commonly caused by poor oral and facial muscle control. Sialorrhea can lead to significant physical and psychosocial complications, including perioral chapping, dehydration, infection, foul odor, stigmatization, and increased dependency and level of care, all of which can create an additional burden for these medically complicated patients. Sialorrhea usually is caused by neuromuscular dysfunction, hypersecretion, sensory dysfunction, or anatomic (motor) dysfunction. The most common cause is neuromuscular dysfunction. Anterior sialorrhea is diagnosed by the observation of excessive drooling. Posterior sialorrhea can be suggested by the history of choking and repeated pneumonias. Treatment for Sialorrhea range from conservative (i.e., observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy.

 

"Sialorrhea - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sialorrhea pipeline landscape is provided which includes the disease overview and Sialorrhea treatment guidelines. The assessment part of the report embraces, in depth Sialorrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sialorrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sialorrhea R&D. The therapies under development are focused on novel approaches to treat/improve Sialorrhea.

Sialorrhea Emerging Drugs Chapters

This segment of the Sialorrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Sialorrhea Emerging Drugs

 

NT0502: Aytu BioPharma

NT0502 (N-desethyloxybutynin) is an oral, once- or twice-daily potential treatment to reduce chronic sialorrhea in patients with neurological and other conditions associated with drooling and excessive salivation. In December 2020, Aytu BioScience and Neos Therapeutics announced that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction. In March 2022, Aytu BioScience announced close of merger with Neos Therapeutics. . NT0502 is currently in Phase 1 clinical development for treatment of chronic sialorrhea.

Further product details are provided in the report……..

Sialorrhea: Therapeutic Assessment

This segment of the report provides insights about the different Sialorrhea drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Sialorrhea

There are approx. 3+ key companies which are developing the therapies for Sialorrhea. The companies which have their Sialorrhea drug candidates in the most advanced stage, i.e. Phase II include, Aytu BioPharma.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Sialorrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sialorrhea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sialorrhea therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sialorrhea drugs.

Sialorrhea Report Insights

• Sialorrhea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sialorrhea Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Sialorrhea drugs?
• How many Sialorrhea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sialorrhea?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sialorrhea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sialorrhea and their status?
• What are the key designations that have been granted to the emerging drugs?